BioCardia, Inc. Increase (Decrease) Due from Other Related Parties
BioCardia, Inc. (BCDA) reported Increase (Decrease) Due from Other Related Parties of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseDueFromOtherRelatedParties · last filed 2023-05-10
- BioCardia, Inc. increase (decrease) due from other related parties for the quarter ending 2023-03-31 was $0.00.
- BioCardia, Inc. increase (decrease) due from other related parties for the quarter ending 2022-12-31 was $0.00.
- BioCardia, Inc. increase (decrease) due from other related parties for the quarter ending 2022-09-30 was $0.00.
- BioCardia, Inc. increase (decrease) due from other related parties for the quarter ending 2022-06-30 was $0.00.
- BioCardia, Inc. increase (decrease) due from other related parties for fiscal 2022 was $0.00.
- BioCardia, Inc. increase (decrease) due from other related parties for fiscal 2021 was -$618.00K, a 200.00% decline from fiscal 2020.
- BioCardia, Inc. increase (decrease) due from other related parties for fiscal 2020 was $618.00K.
| Period end | Increase (Decrease) Due from Other Related Parties 3 month | Increase (Decrease) Due from Other Related Parties 6 month | Increase (Decrease) Due from Other Related Parties 9 month | Increase (Decrease) Due from Other Related Parties 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-05-10 | $0.00 derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 derived: sum of 3 quarters · filed 2023-03-29 | $0.00 10-K · filed 2023-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | -$562.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | -$562.00K derived: sum of 3 quarters · filed 2023-05-10 | -$562.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | -$562.00K derived: sum of 2 quarters · filed 2023-05-10 | -$562.00K derived: sum of 3 quarters · filed 2023-05-10 | -$623.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$562.00K derived: sum of 2 quarters · filed 2023-03-29 | -$623.00K derived: sum of 3 quarters · filed 2023-03-29 | -$618.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$61.00K derived: sum of 2 quarters · filed 2022-11-09 | -$56.00K 10-Q · filed 2022-11-09 | -$200.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$56.00K 10-Q · filed 2022-08-10 | -$200.00K derived: sum of 3 quarters · filed 2022-08-10 | $43.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $5.00K 10-Q · filed 2022-05-11 | -$139.00K derived: sum of 2 quarters · filed 2022-05-11 | $104.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $99.00K derived: sum of 2 quarters · filed 2022-03-29 | $618.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $762.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $519.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |